Federal Circuit Affirms Preliminary Injunction Against NeoGenomics in US Liquid Biopsy Patent Case (patsnap.com)

• Federal Circuit affirms preliminary injunction against NeoGenomics
• Patents US11530454B2 and US11519035B2 at issue
• Natera prevails in liquid biopsy patent dispute
• Decision dated July 12, 2024

"The U.S. Court of Appeals for the Federal Circuit affirmed a preliminary injunction against NeoGenomics in favor of Natera, regarding patents covering liquid biopsy methods (US11530454B2 and US11519035B2). The July 12, 2024 ruling strengthens enforcement of foundational genomic diagnostics patents, impacting NeoGenomics' testing services and signaling increased risk for competitors in cfDNA and multiplex PCR technologies."